颈动脉产品介绍 - 支架-in service.ppt

《颈动脉产品介绍 - 支架-in service.ppt》由会员上传分享，免费在线阅读，更多相关内容在工程资料-天天文库。

1、CarotidWALLSTENTTM颈动脉支架®支架自膨支架Elgiloy®金属丝编制管状网眼结构2支架输送系统Monorail™导管设计，0.014“导丝输送系统；5F(6&8mm)和6F(10mm)低外廓，高柔顺性；CarotidWALLSTENTTM颈动脉支架闭环设计跟踪性极佳的SDS-支架输送系统卓越的显影性独特的可回收能力*唯一经FDA批准可用于双侧治疗颈动脉支架**临床数据支持*Pleasenotethatreconstrainmentandrepositioningaresubjecttospecificlimi

2、tations.PleaserefertoDFUcautionsandwarningsforadditionalinformation.**TheCarotidWALLSTENTEndoprosthesisisindicatedforuseineligiblepatientswithipsilateralorbilateralcarotidarterydiseaseCarotidWALLSTENTTM颈动脉支架闭环单元结构，独特的支架设计提供最大化的斑块覆盖高度的柔顺性便于使用的输送系统*FreeCellArea:Measur

3、estheaveragearea(mm2)withintheperimeterofconnectingstruts.Smallernumber=smallerfreecellarea.CarotidWALLSTENTTM颈动脉支架支架设计-闭环Vs.开环闭环支架设计CarotidWALLSTENT®EndoprosthesisXact®CarotidStent开环支架设计Precise®PRORxNitinolStentSystemRXAcculink®CarotidStentCarotidWALLSTENTEndoprost

4、hesisPrecisePRORxNitinolStentSystemRXAcculinkCarotidStentImagestakenbyandonfileatBSC.IllustrationsbyBSC.PreciseProisatrademarkofCordisCorporation,AcculinkisatrademarkofAbbottCardiovascularSystems,Inc,andXactistrademarkofMedNova,Ltd.闭环支架设计CWS与其他颈动脉支架相比，具有最小的支架网孔面积**C

5、arotidWALLSTENT®闭环设计提供最大化的斑块覆盖以及光滑平整的管腔**TestingperformedonCarotidWALLSTENTEndoprosthesis8mmx21mm,PreciseProRX8mmx40mm,RXACCULINK7-10mmx40mm,Xact7-9mmx40mm.Benchtestresultsmaynotnecessarilybeindicativeofclinicalperformance.Testresultsshownareformodelsdeemedmosttypic

6、allyselectedforplacementincommoncarotidarterywithareferencediameterof<8mm.Othermodelswerealsotestedandyieldedsimilarresults.N=3.Dataonfile.PreciseProisatrademarkofCordisCorporation,AcculinkisatrademarkofAbbottCardiovascularSystems,Inc,andXactistrademarkofMedNova,Ltd

7、.*FreeCellArea:测量支架连接小杆周长间的平均面积数值越小=支架网孔面积越小PhotographstakenbyBostonScientificCorporation闭环支架设计CarotidWALLSTENT®闭环设计提供最大化的斑块覆盖以及光滑平整的管腔DoesCarotidStentDesignInfluenceOutcomes?R.M.Bersin,CatheterizationandCardiovascularInterventions2008;72:863–866目前为止，已经完成3项有关颈动脉支架设计

8、与临床结果的回顾性、非随机研究。DoesFreeCellAreaInfluencetheOutcomeinCarotidArteryStenting?Bosiersetal.Aretrospectiveanalysisof30dayoutcomesofacarotidarte